Erythropoiesis-stimulating agents in cancer patients: ESMO Recommendations for use

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Scrijvers, D ^a   Roila, F ^b  

^a Ziekenhuis Antwerpen Middelheim   (Belgium)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW EXAMINATION; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED DISEASE; COOMBS TEST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; GYNECOLOGIC CANCER; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; IRON DEFICIENCY ANEMIA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE; URTICARIA; VITAMIN SUPPLEMENTATION;

EID: 66549107662     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp161     Document Type: Article

References (16)

1. Blanc B, Finch CA, Hallberg L et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968; 405: 1-40.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
3. Ludwig H, Van Belle S, Barrett-Lee et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
4. Mercadante S, Gebbia V, Marrazzo A et al. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303-311.
5. Wilson J, Yao GL, Raftery J et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11: 1-202.
6. http://ctep.info.nih.gov/reporting/ctc_archive.html (16 March 2008, date last accessed).
7. Harper P, Littlewood T. Anaemia of cancer: Impact on patient fatigue and longterm outcome. Oncology 2005; 69 (Suppl 2): 2-7.
8. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 (Suppl 1): 22-34.
9. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review. Cancer 2002; 94: 2793-2796.
10. http://www.emea.europa.eu/humandocs/Humans/EPAR (17 March 2008, date last accessed.
11. Smith RE, Aapro M, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1040-1050.
12. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoetin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3: CD003407.
13. Ross SD, Allen IE, Probst CA et al. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: A systematic review and metaanalysis. Oncologist 2007; 12: 1264-1273.
14. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
15. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618.
16. Bennett CL, Luminari S, Nissenson AR et al. Pure red cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408.